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Abstract: Even though pharmaceutical care is not a new concept in pharmacy, its introduction and
development has proved to be challenging. In Iceland, general practitioners are not familiar with
pharmaceutical care and additionally no such service is offered in pharmacies or primary care settings.
Introducing pharmaceutical care in primary care in Iceland is making great efforts to follow other
countries, which are bringing the pharmacist more into patient care. General practitioners are key
stakeholders in this endeavor. The aim of this study was to introduce pharmacist-led pharmaceutical
care into primary care clinics in Iceland in collaboration with general practitioners by presenting
different setting structures. Action research provided the framework for this research. Data was
collected from pharmaceutical care interventions, whereby the pharmaceutical care practitioner
ensures that each of a patient’s medications is assessed to determine if it is appropriate, effective, safe,
and that the patient can take medicine as expected. Sources of data included pharmaceutical care notes
on patients, researcher’s notes, meetings, and interviews with general practitioners over the period
of the study. The study ran from September 2013 to October 2015. Three separate semi-structured
in-depth interviews were conducted with five general practitioners from one primary health care
clinic in Iceland at different time points throughout the study. Pharmaceutical care was provided to
elderly patients (n = 125) before and between general practitioners’ interviews. The study setting was
a primary care clinic in the Reykjavik area and the patients’ homes. Results showed that the GPs’
knowledge about pharmacist competencies as healthcare providers and their potential in patient
care increased. GPs would now like to have access to a pharmacist on a daily basis. Direct contact
between the pharmacist and GPs is better when working in the same physical space. Pharmacist’s
access to medical records is necessary for optimal service. Pharmacist-led clinical service was deemed
most needed in dose dispensing polypharmacy patients. This research indicated that it was essential
to introduce Icelandic GPs to the potential contribution of pharmacists in patient care and that action
research was a useful methodology to promote and develop a relationship between those two health
care providers in primary care in Iceland.
Keywords: pharmacists; pharmaceutical care; general practitioners; primary care; action research
1. Introduction
The pharmacy profession has increasingly been making individualized care plans for patients [1]
since Hepler and Strand described the term pharmaceutical care practice in 1990 [2]. Pharmaceutical
care represents a patient-centered approach where the pharmacists, in collaboration with other health
care professionals, are responsible for patients’ drug therapy. The purpose is to achieve positive
outcomes intended to improve the patient's quality of life. The pharmaceutical care practitioner
ensures that each of a patient´s medications (prescription, nonprescription, alternative, or traditional
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medicines) is assessed to determine if it is appropriate, effective, safe, and that the patient is able to
take medicine as expected [3–5]. The service can be provided in different settings of care; pharmacies,
primary, secondary, and tertiary care [6,7]. Sometimes, the pharmaceutical care practitioners are
employed in the primary care clinics and practice full-time or part-time in the clinic providing this
service [8]. Other pharmaceutical care practitioners are located outside of the primary care clinic in
the community pharmacy [9], in the hospital setting [10], or as self-employed consultants [9]. Even
though reliable data have pointed out that pharmaceutical care can lead to progress in health outcomes
and cost-effective therapy [11], and positive impact on Health-Related Quality-of-Life Outcomes [12],
the implementation has not been as fast as one might have expected [13,14]. Lack of time and
attitudes/opinions of other professionals, clinical education, communication skills, and remuneration
have been reported as barriers to implementation. It should be noted that barriers are not the same in
all countries [15–18].
In Iceland, pharmaceutical care services are provided in hospitals but not in other settings of care,
despite the requirement for pharmaceutical care provision being written into legislation in 1994 [19].
The main challenge in Iceland is that, currently, there is little communication between community
pharmacists and general practitioners (GPs) on clinical issues [20], even though globally pharmacists
are taking on a larger role as primary care patient care providers [1]. GPs do not recognize pharmacists
as health care providers, nor do they have any experience with pharmacist-led clinical services [20].
International studies abound on the impact of clinical pharmacy services on patient outcomes [21]
and some interventions have focused on pharmacist–GP cooperation [22]. To date, studies have not
focused on the actual process when pharmacists develop an outpatient service, where none exists, in
close collaboration with GPs.
The aim of action research methodology is to facilitate continuous improvement and
involvement [23]. Since the implementation of pharmaceutical care is shown to be challenging,
this approach was chosen for this study. It was also hoped that it could contribute to making the
development and implementation as successful as possible. Therefore, the aim of this study was to use
action research methodology to introduce and study pharmacist-led pharmaceutical care in primary
care in collaboration with GPs and to test this model in different settings with the goal of meeting
specific local and Icelandic needs.
2. Materials and Methods
2.1. Research Design
The origins of action research are often credited to the social psychologist Lewins at the end of the
Second World War [24]. Reason and Bradbury [25] describe action research as a “family of approaches”
where both quantitative and qualitative research methods are used. It is based on a different paradigm
from other research because traditionally the researchers do a study on people but action researchers
do research with people [26]. The action research process focuses on action and change. The overall
characteristic of action research is the use of cycles aiming to meet identified needs. The process steps
are: diagnosing and analyzing problems, planning, implementing/taking action, and evaluating. After
the evaluation, a new cycle can start based on the new situation [25–27].
In this case, the problem was how to introduce and adapt the pharmaceutical care service into the
Icelandic primary care clinics. Action research was used as it was expected that several cycles would be
needed to get to a process that was feasible for the existing organization and at the same time providing
benefit to patients. By involving and making GPs active in decisions about the implementation,
it was expected that they would be more willing to accept pharmacist-led pharmaceutical care.
An active participation strategy was used; the first author was active in introducing and starting
the service, i.e., being a practitioner, while at the same time being a researcher. The process started by
understanding GPs’ perspectives and introducing a service, which was then modified throughout the
action research cycles.
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2.2. Setting
The study settings were one primary care clinic in the Reykjavik area and homes of patients who
received the pharmacist-led pharmaceutical care. In Iceland, publicly funded primary care clinics
were established four decades ago offering services to the whole population. They are intended to
be the patient´s first point of contact to the health care system, although GPs do not have a formal
gatekeeping role. The primary care clinics offer various health and nursing services, general medical
service, general nursing care, infant and maternity service, school nursing, vaccinations for adults, and
other services. They are located all around the country and offer different kinds of service depending
on location [28]. The primary care clinic participating in the research is situated in the Reykjavik area
and provides all of the services mentioned above.
Five GPs from the primary care clinic (three females and two males) and 125 of their patients
participated in the action research process. The primary care clinic GPs chose participants over
65 years of age based on the risk criteria established by the Home Medicines Review (HMR) program
in Australia [29]. GPs then made a referral to the pharmacist for pharmaceutical care service. The
choice of criteria was based on that they have shown works well in identifying patients in need of
pharmaceutical care [29] and that they were well accepted by GPs.
2.3. Data Collection and Analysis
Data was collected from pharmaceutical care interventions with patients, research notes, meetings,
and in-depth interviews with GPs throughout the study, which ran from September 2013 to
October 2015.
Pharmaceutical care intervention: The researcher provided pharmaceutical care as defined in the
pharmaceutical care literature [3–5] to 125 patients throughout the study. Here the pharmaceutical care
practitioner ensured that each of a patient´s medication was assessed to determine if it was appropriate,
effective, safe and that the patient was able take medicine as intended. Twenty-five patients received
care in a pilot phase, 50 elderly home-dwelling patients in the first round of the action research process
with no access to their medical records. In the second round, 50 elderly home-dwelling patients
receiving dose dispensed medicines received pharmaceutical care services at the primary care clinic
where the pharmacist had access to the patients’ medical records.
In-depth interviews with GPs: Three in-depth interviews with each of the five GPs were conducted.
Interviews were audio-recorded, transcribed verbatim, and thematically analyzed independently by
the first and last authors. Themes were discussed among the researchers for agreement. Coding and
thematic analysis were undertaken using conventional content analysis [30] and NVivo 11. Data were
evaluated in the Icelandic (original language) and relevant quotes were translated into English. The
first round of in-depth interviews studied the GPs’ perspectives on various issues, the past decade’s
development of primary care in Iceland, today’s status regarding medicine use and monitoring, GPs’
use and perception of pharmacists, and their vision for primary care in the future. Specifics were
sought regarding the pharmaceutical care service, the GPs’ perceptions of the pharmacist-provided
pharmaceutical care at the outset, their views on possible patient health outcomes, resource utilization,
ways of collaborating, the pharmacist’s physical location, and remuneration for the service. In the
second round, GPs were asked about the pros and cons of the service provided and their views on
collaboration with the pharmacist on clinical issues. Also, some practical matters such as the structure
of the report given to them by the pharmacist and how they chose patients in the research. In the third
round of interviews, GPs were asked the same questions as in the second round. Additionally, their
views on differences between the two ways of providing pharmaceutical care, their ideas about the
best way to provide this service in primary care in the future and their current opinion of pharmacists
and their role in patient care were asked for.
Meetings: Throughout the duration of the project, three meetings were held between the
participating pharmacist and the participating GPs. The meetings were conducted to explore the
progress of the project and to find common ground on which to move forward. The meetings were
Pharmacy 2017, 5, 23 4 of 11
not recorded, but notes were taken and minutes were written up including ideas, discussions, and
decisions made.
Research notes: Throughout the entire project, the participating researcher kept notes of her
experience. These notes consist of descriptions of events to document the project´s process and
progress. These notes supplemented the data and were used to further understand the project,
interventions, GP meetings, and interviews. The participating researcher continuously reflected on
the data by speculating on the issues and what had been planned, discovered, and achieved during
the process.
2.4. Ethical Approval
Ethical approval (Nr. 12-218) was obtained from the National Bioethics Committee and The Data
Protection Authority in Iceland.
3. Results
3.1. Description of Action Research Cycles
Throughout the process of the study period, one action led to another, and two cycles emerged as
shown in Figure 1.
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The cycles are described in detail below, but Table 1 provides an overview of the process.
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Table 1. Overview of the two action research cycles. The time period and stage within each cycle are
shown, and for each stage, the specific objectives, process, and output leading to the subsequent stage.
Time Period/Cycle Stage Objective Process Output
September to December 2013
Diagnosing the problem cycle one
Understand GPs’
perspective on various issues
Conduct and analysis of
the first round of
in-depth interview with
participant GPs
There are several unmet needs
regarding medicines and patient
monitoring, and GPs are not familiar
with pharmacist clinical service.
January 2014
Plan cycle one
Find common ground to
move forward with the
program from the results
Meeting with
participating GPs
GPs are unfamiliar with pharmacist
services. It was decided to provide
pharmaceutical care to 50 patients and
focus on elderly home dwelling
polypharmacy patients and then
interview GPs immediately after.
February to October 2014
Action cycle one
Provide pharmaceutical care
and focus on polypharmacy
patients
Pharmaceutical care
process as defined by
Cipolle et al. [3–5]
The participating researcher provided
pharmaceutical care to 50 elderly
home-dwelling patients with no
access to medical records.
November and December 2014
Action cycle one
Get GPs views on the
pharmacist service provided
Conduct of the second
round of in-depth
interviews with GPs
The second round of in-depth
interviews with participating GPs.
December 2014 and January 2015
Evaluation/Reflection cycle one
Describe the results from the
pharmaceutical care
intervention and in-depth
interviews
Analysis of the second
round of interviews with
GPs and research notes
GPs found the pharmaceutical care
service useful but that it needed
more structure.
They found the service most needed
in dose dispensing
polypharmacy patients.
Pharmacist needed medical records
and increased contact with GPs to
provide proper pharmaceutical
care service.
January 2015
Plan cycle two
Find common ground to
move forward with
the program
Meeting with
participating GPs
It was decided to provide
pharmaceutical care to 50 dose
dispensing patients at the primary
care clinic with access to medical
records and then interview GPs
immediately after.
February to June 2015
Action cycle two
Provide pharmaceutical care
and focus on polypharmacy
dose dispensing patients
Pharmaceutical care
process as defined by
Cipolle et al. [3–5]
The participating researcher provided
pharmaceutical care to 50 patients.
The service was provided at the
primary care clinic with access to
medical records.
June 2015
Action cycle two
Get GPs’ views on the
pharmacist service provided
Conduct of the third
round of in-depth
interviews with GPs
The third round of in-depth
interviews with participating GPs.
August to October 2015
Evaluation/Reflection cycle two
Describe the result from the
pharmaceutical care
intervention and in-depth
interviews
Analysis of the third
round of interviews and
research notes
GPs found this second type of
intervention to be an improvement
and that it gave useful input into
clinical decision-making.
Direct contact between the pharmacist
and GPs is increased when working
in the same physical space.
Pharmacist’s access to medical
records is necessary for optimal care.
3.2. Cycle One
3.2.1. Diagnosing the Problem
The first round of interviews while planning cycle one showed several unmet needs regarding
medicines and patient monitoring in the Icelandic health care system. GPs suggested ways in which
these gaps could be addressed and pharmacist-led pharmaceutical care was one of the suggestions.
The GPs’ communication with pharmacists in the primary care setting mostly surrounded practical
issues—not clinical.
They were not familiar with pharmaceutical care service, but due to polypharmacy and various
other drug-related problems, they found that pharmacists should be more involved in patient care.
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3.2.2. Plan
A meeting was held with GPs participating in the study to find common ground moving forward
with the study based on the results of diagnosing the problem. The results of the meeting were to
introduce pharmacist-led pharmaceutical care service to GPs personally and then interview them
immediately after. The focus was put on elderly home-dwelling polypharmacy patients, and the
participating researcher had no access to patients’ medical records.
3.2.3. Action
The participating researcher provided pharmaceutical care to 50 elderly home-dwelling
polypharmacy patients with no access to medical records. Then, she interviewed participating GPs.
3.2.4. Evaluation/Reflection
Results from the second round of GP interviews revealed that GPs found the service useful, but
at the same time they found it needed to be more structured. After the pharmacist had met with the
patient, the doctor did not see him/her subsequently, and therefore the doctors did not review the
pharmacist’s report immediately. It was pointed out that “this administration takes too much time, call
the patient and get a hold of him you understand this will increase our work so I would like it to be
more streamlined” (Interview 2, Participant 3).
GPs thought pharmacists’ education should be concerned more with providing patient care.
Because GPs had difficulties reviewing patients’ drug lists on a daily basis, they found themselves
needing the pharmacist’s clinical service. One doctor mentioned, “In the daily work at the clinic you
don’t have time [to review the patient’s medication list] because of too many tasks, and too few GPs
[being] employed [at the clinic]” (Interview 2, Participant 4). Due to structural issues, they thought the
service was most needed for dose dispensed polypharmacy patients. In Iceland patients who get their
medications dose dispensed are prescribed the medicines on a one-year basis. One doctor said, “Today,
dose dispensed patients are more likely to be automatically prescribed than others” (Interview 2,
Participant 1).
The researcher as a pharmaceutical care provider identified the need for medical records providing
this service. Many of the pharmacist’s comments could be omitted if clinical information on the patient
was available. Also, in the researcher’s opinion, the distance between her and the GPs led to fewer
communications crucial for the proper pharmaceutical care of patients.
3.3. Cycle Two
3.3.1. Plan
A second meeting with the GPs was held to explore the progress and to find common ground
to move forward with the program. The GPs found themselves needing the pharmacist’s service
in dose dispensing polypharmacy patients due to structural issues and also because they found the
service process needed to be more explicit. From the pharmacist’s point of view, there was a lack of
communication as well as the lack of access to medical records. Therefore, it was decided that the
participating researcher would provide pharmaceutical care to dose dispensing patients at the primary
care clinic with access to medical records and then interview GPs immediately after.
3.3.2. Action
The participating researcher provided pharmaceutical care to 50 dose dispensing patients at the
primary care clinic with access to medical records. She then interviewed participating GPs on the
pharmacist service provided.
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3.3.3. Evaluation/Reflection
GPs’ view of pharmacists as health care providers:
It was clear in the third round of interviews that the GPs had much more to say about pharmacists
than at the beginning of the project and their comments were more precise and to the point.
All participants thought highly of pharmacists, even though they had little or no connections with
pharmacists regarding clinical issues. They agreed that seeing the pharmacist in practice increased their
positive view of pharmacists. One doctor said; “I’m happy that they are focusing more on consumers
that patients are important not just the pills” (Interview 3, Participant 3). Another said; “This project
has increased my positive attitude towards pharmacists” (Interview 3, Participant 4). Yet another GP
said, “I have to answer this in the affirmative now that I have seen how you work [as a pharmacist]”
(Interview 3, Participant 1).
Pharmacist-led pharmaceutical care:
At the end of the study process, GPs had experienced pharmacist-led pharmaceutical care service
personally in two different settings. All GPs thought it was a good quality control on prescribing and
they did not have any negative attitudes towards the service provided. The only challenge remaining
was the lack of time spent reviewing patient reports from the pharmacist. They found the service to be
useful and pointed out the pharmacists’ comments about interactions, adverse drug reactions, and
indications as very helpful input into clinical decision-making. Also, they appreciated getting tips
regarding drugs that are rarely used. The input demanded by the GPs from the pharmacist changed
significantly over the study period. At the beginning of the project, the GPs focused mostly on the
pharmacist providing information about interactions, but by the end, other issues were considered,
as mentioned above. One experienced doctor said “This [pharmacist service] is a new angle when
you look at pharmacist involvement in patients’ medicines, and it is real progress and a quality
improvement that lifts up the operation of the primary care clinic” (Interview 3, Participant 4). Another
said “I think this [pharmacist service] is great. There is information that I have received that I had not
been aware of or didn't know about, so you learn a lot” (Interview 3, Participant 5).
All GPs found the service helpful and agreed that it would, in the long-term, facilitate the GPs’
practice. One GP summed it up “We have a lot of patients who see different doctors and are consuming
lots of drugs, and we [as GPs] have difficulties reviewing whether all the drugs are necessary and so
on” (Interview 3, Participant 5).
The future of GP-pharmacist collaboration in Iceland:
All GPs participating in the research openly stated that they felt pharmacists should work at the
primary care clinic and be a part of the healthcare team as a medicines expert. When analyzing their
comments from interview one to three, and focusing on the differences between the interventions,
it was clear that they were more pleased with the last intervention, which took place at the primary
care clinic. The main reason stated by all participants was because of the face-to-face communication.
One GP said “I think that the presence of these health professionals such as doctors and pharmacists
that you recognize faces and you have spoken to each other is priceless. So, working at a close distance
between these health professionals is a good thing” (Interview 3, Participant 4).
GPs mentioned other practical issues such as pharmacist access to medical records, pharmacists
having other roles working at the clinic (such as educating other health care providers), and the
pharmaceutical care service needing to be well structured and streamlined to have benefits. However,
they had all throughout the process mentioned the importance of the face-to-face communication.
4. Discussion
This study aimed to introduce and subsequently study pharmacist-led pharmaceutical care in
primary care in collaboration with GPs using action research methodology. The main findings of
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this study are that GPs’ knowledge about pharmacists as patient care providers developed during
the research period. Second, GPs found it better when pharmacist and GPs worked side by side in
clinical decision-making, and they would like to have access to a pharmacist on a daily basis. Lastly,
pharmacist access to medical records is necessary for an optimal service.
Since pharmacists are not always considered as patient care providers in contrast to nurses and
doctors, it is important to introduce pharmacist-led clinical services in a systematic manner. It can be
assumed that, to implement a new health care service successfully, the service has to be needed not by
the provider (the pharmacist) but by others, for example, groups such as patients, doctors and nurses.
These groups cannot demand services that they do not recognize as necessary. The main challenge
regarding pharmacist-GP collaboration in Iceland is that GPs neither know pharmacists as health
care providers nor their clinical services [20]. This study was the first in introducing pharmacists as
potential patient care providers in an established primary care clinic in Iceland. The results show
that the more GPs are familiar with the service, the more they find it useful. This particular result
has been reported by other researchers [31]. In addition, developing a trusting relationship is an
important factor for efficient collaboration [32,33]. In our study, the pharmacist established credibility
as a team member by working as a patient care provider and answering drug-related questions.
Other studies have shown that pharmacists working with physicians as an information resource
has established credibility [34]. Another crucial part is that the pharmacist service needs to be well
structured to benefit GPs. Giving them an opportunity to structure the service in an action research
process with the pharmacist, enhanced their buy-in and appreciation of the new service. To build a
good interdisciplinary unit, it is important that participants identify the role, purpose, and a clear
vision for the team [35]. Due to the GPs’ current heavy workload, and since this is a new service to
them, they did not at the outset fully understand the role of the pharmacist. This research was initiated
to remedy that.
It was surprising that GPs wanted the participating researcher to focus the clinical effort on dose
dispensed patients since they already receive a simple medication review (based on the medication
history in the pharmacy) by a pharmacist. However, a systematic review by Sinnemäki et al. [36]
revealed that dose dispensing patients are more at risk of having the drug treatment unchanged for
an extended period. Possible reasons are likely—as the GPs in this research pointed out—that dose
dispensed patients are often prescribed medicines for a long time without a GP or a clinical pharmacist
reviewing their medication list.
Another issue, which is important to consider, is various locations and needs for the service. Since
pharmacist clinical service is new in primary care in Iceland, it is not possible to have a pharmacist in
every clinic due to lack of pharmacists working in patient care. Therefore, it is necessary to make an
implementation plan taking into account factors such as the number of elderly patients, the prevalence
of polypharmacy, the primary care clinic structure, and which clinics are in most need of pharmacist
service. USA, Canada, and the UK are examples of countries that have integrated pharmacists into
primary care [37–39].
A single action research study, which introduces pharmacist-led pharmaceutical care in
collaboration with GPs, is not sufficient to get clinical pharmacy services on track in Iceland.
As mentioned above, the literature pointed out different barriers to implementation, such as lack
of time and attitude/opinion of other professionals, clinical education, communication skills, and
remuneration [15–18]. In order to successfully roll out the service to other clinics in Iceland, a workforce
plan taking our findings and all those other factors into consideration is needed.
By using action research methodology, the research was able to adapt to the context and setting,
making the success of implementation more probable. Those aspects were crucial in this study because
it allowed the project to constantly develop in the primary care clinic and to change along the way.
Also, by collaborating with the GPs, different perspectives were presented, and this increased the
project’s validity and efficiency.
Pharmacy 2017, 5, 23 9 of 11
This study has a few limitations worth mentioning. First, in action research, the close relationships
between the researcher and participants have been criticized, which can easily introduce biases.
Conversely, it has been reported that this closeness can result in more valid data [40]. This can also
be a limitation in the data analysis. However, two researchers not directly involved in the process
(the second and third authors) also analyzed and interpreted the data. When introducing a healthcare
profession in the team, it is vital for this professional to collaborate with other team members [35].
In Iceland, doctors and nurses are currently the only health professions that play a significant role in
the primary care clinics with very little input from other health care professions. Therefore, the second
limitation of our study is that nurses were not involved in the project. Third, action research can be
time-consuming and a few months are often insufficient duration to establish a permanent connection
and trust, although in this case, the pharmacist managed to build trust with the GPs and staff during
this period. Last, because this research took place on a local scale, it cannot be generalized to a broader
context. Nonetheless, the process and the results of it can be an inspiration for other settings.
5. Conclusions
When implementing pharmaceutical care practice, many barriers have been noted in the literature.
In Iceland, the lack of communication between GPs and pharmacists was one of them. This research
indicated that action research is a useful methodology to promote and develop a relationship between
those two health care providers in primary care. The most efficient collaboration is when pharmacists
and GPs work side by side at the primary care clinic.
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